Stuart Jacob, DPM
Foot & Ankle Surgery · Burlington, NJNPI 1538156963
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AbbVie at 32.6% of the total. Reporting peaked in 2024 at $183 and has fallen 77.3% since, to $42 in 2025. That places this record below the midpoint for foot & ankle surgery clinicians in NJ, where the typical reported total is $1,926.
Across 7 payments — averaging $56.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$130
- Organogenesis Inc.$112
- Stryker$86
- Kerecis Limited$42
- Integra Lifesciences Corporation$20
- Aroa Biosurgery Incorporated$9
What the payments were for
- Food & beverage$399100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $130 |
| Organogenesis Inc. | 2 | $112 |
| Stryker | 1 | $86 |
| Kerecis Limited | 1 | $42 |
| Integra Lifesciences Corporation | 1 | $20 |
| Aroa Biosurgery Incorporated | 1 | $9 |
How this compares
$399 in reported general payments places this provider in the 15th percentile of 542 foot & ankle surgery providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 83 | $2,703 |
| Betamethasone Dipropionate | 20 | $504 |
| Doxycycline Hyclate | 24 | $210 |
| Mupirocin | 15 | $151 |
| Silver Sulfadiazine | 17 | $151 |
| Cephalexin | 23 | $106 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Burlington
- John CozzarelliBelleville$932K
- Matthew RegulskiToms River$843K
- Michael SubikLyndhurst$529K
- Krupa PatelMorris Plains$281K
- Johanna GodoyWayne$254K
- Andrew BriefRidgewood$253K
- Mark SolomonCedar Knolls$232K
- Evan AdlerOld Bridge$195K
- Shane HollawellManasquan$169K
- Jacob ReinkrautRidgewood$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.